Germany clinical trial supply market size is projected to reach USD 206.0 million by 2025, in terms of revenue. Growing number of clinical trial studies in Germany is expected to keep the market buoyant over the coming years. Increasing complexity of conducting trials is driving the competition in the industry as a large number of clinical supplies companies are investing millions in IT and cold chain facilities.
Growth in number of sites per study and changing study design of clinical trials along with increased number of new drug trials, which are tested against an approved marketed drug, are responsible for the growing complexity in clinical trials. Rising need for supply chain planning, software for inventory management, and ancillary supply chain management is also likely to contribute towards the growth of the Germany clinical trial supplies market.
According to the clinical trial logistics survey by Nice Insights, 35.0% of Phase III clinical trials are outsourced and it is anticipated to increase further on account of growing number of investigational drugs advancing to the next phase. This trend is expected to stimulate the demand for efficient supply chain and logistics, thereby contributing to the industry growth.
Germany clinical trial supplies market in oncology sector comprises primary, as well as secondary packaging. The objective of packaging is to better manage and improve patient compliance. Packaging must prevent gases from aerosolizing and protect vials from leakage. Packaging is completed in accordance to the dosage requirement. The metabolic disorders segment is predicted to grow on account of government funding for clinical trials.
For instance, according to the National Center for Biotechnology Information, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsored clinical trials for diabetes in 2016. The manufacturing activity at times is higher for post market drugs, thereby leading to rising demand for supplies. In addition, certain drugs, medical devices, and other healthcare products are mandated to undergo further testing by the FDA, which contributes to generation of revenue.
The number of products undergoing further testing and increasing stringency in management are fueling the industry growth. Major companies operating in this industry include The Almac Group; Biocair International Ltd.; Catalent, Inc.; KLIFO A/S; Movianto. Collaborations and acquisitions activities undertaken by the industry players are likely to increase the competition in the market.
Access full report or request for free sample at: https://www.hexaresearch.com/research-report/germany-clinical-trial-supplies-market
Hexa Research has segmented the Germany clinical trial supplies market report based on phase, product & service, end-use and therapeutic use:
Segmentation by Phase, 2014 - 2025
• Phase I
• Phase II
• Phase III
Segmentation by Product & Service
• Manufacturing
• Storage & Distribution
• Supply Chain Management (SCM)
Segmentation by End-use
• Pharmaceutical
• Biologics
• Medical Devices
• Others
Segmentation by Therapeutic Use
• Oncology
• CNS
• Cardiovascular
• Infectious Disease
• Metabolic Disorders
• Others
Key players analyzed:
• Almac Group
• Biocair
• Catalent, Inc.
• KLIFO
• Movianto
• PCI Pharma Services
• PAREXEL International Corporation
• Sharp Packaging Services
• Thermo Fisher Scientific Inc.